Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.

Li XD, Han JC, Zhang YJ, Li HB, Wu XY.

Asian Pac J Cancer Prev. 2013;14(1):145-8.

PMID:
23534713
[PubMed - indexed for MEDLINE]
Free Article
2.

Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.

Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H, Zhong R, Xu Y, Wu J, Yu D, Wu T, Zhang X, Nie S, Miao X, Lin D.

Lung Cancer. 2011 Jul;73(1):110-5. doi: 10.1016/j.lungcan.2010.11.004. Epub 2010 Dec 3.

PMID:
21129812
[PubMed - indexed for MEDLINE]
3.

Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.

Zhang L, Ma W, Li Y, Wu J, Shi GY.

Genet Mol Res. 2014 Jan 14;13(1):228-36. doi: 10.4238/2014.January.14.2.

PMID:
24446315
[PubMed - indexed for MEDLINE]
Free Article
4.

Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.

Ke HG, Li J, Shen Y, You QS, Yan Y, Dong HX, Liu JH, Shen ZY.

Asian Pac J Cancer Prev. 2012;13(9):4413-6.

PMID:
23167352
[PubMed - indexed for MEDLINE]
Free Article
5.

[XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].

Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Sun Y, Zhang XR, Xu BH, Lin DX.

Zhonghua Zhong Liu Za Zhi. 2006 Mar;28(3):196-9. Chinese.

PMID:
16875604
[PubMed - indexed for MEDLINE]
6.

Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.

Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, Zhang W, Qian J, Wang J, Chen H, Wei Q, Han B, Lu D.

PLoS One. 2012;7(3):e33200. doi: 10.1371/journal.pone.0033200. Epub 2012 Mar 29.

PMID:
22479369
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

[Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].

Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Sun Y, Xu BH, Lin DX.

Zhonghua Yi Xue Za Zhi. 2005 Apr 13;85(14):972-5. Chinese.

PMID:
16061005
[PubMed - indexed for MEDLINE]
8.

Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.

Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, Garavaglia D, Tofanetti FR, Flacco A, Siggillino A, Baldelli E, Tonato M, Crinò L.

J Thorac Oncol. 2011 Dec;6(12):2018-26. doi: 10.1097/JTO.0b013e3182307e1f.

PMID:
22052224
[PubMed - indexed for MEDLINE]
9.

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.

Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, Song Y.

Med Oncol. 2011 Mar;28(1):315-21. doi: 10.1007/s12032-010-9443-1. Epub 2010 Feb 9. Review.

PMID:
20143185
[PubMed - indexed for MEDLINE]
10.

Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.

Li Y, Huang XE, Jin GF, Shen HB, Xu L.

Asian Pac J Cancer Prev. 2011;12(3):739-42.

PMID:
21627375
[PubMed - indexed for MEDLINE]
Free Article
11.

[Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].

Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Zhang XR, Sun Y, Xu BH, Lin DX.

Ai Zheng. 2005 Dec;24(12):1510-3. Chinese.

PMID:
16351803
[PubMed - indexed for MEDLINE]
12.

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.

Provencio M, Camps C, Cobo M, De las Peñas R, Massuti B, Blanco R, Alberola V, Jimenez U, Delgado JR, Cardenal F, Tarón M, Ramírez JL, Sanchez A, Rosell R.

Cancer Chemother Pharmacol. 2012 Dec;70(6):883-90. doi: 10.1007/s00280-012-1985-9. Epub 2012 Sep 29.

PMID:
23053267
[PubMed - indexed for MEDLINE]
13.

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.

Wang YD, Ha MW, Cheng J, Zhang WL, Cong X, Tong CY, Sun J.

Oncol Rep. 2012 Apr;27(4):979-86. doi: 10.3892/or.2011.1591. Epub 2011 Dec 13.

PMID:
22179630
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.

Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.

Am J Clin Oncol. 2010 Oct;33(5):489-94. doi: 10.1097/COC.0b013e3181b9cedc.

PMID:
20351547
[PubMed - indexed for MEDLINE]
15.

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.

Ren S, Zhou S, Wu F, Zhang L, Li X, Zhang J, Xu J, Lv M, Zhang J, Zhou C.

Lung Cancer. 2012 Jan;75(1):102-9. doi: 10.1016/j.lungcan.2011.05.023. Epub 2011 Jun 14.

PMID:
21676483
[PubMed - indexed for MEDLINE]
16.

Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.

Qin Q, Zhang C, Yang X, Zhu H, Yang B, Cai J, Cheng H, Ma J, Lu J, Zhan L, Liu J, Liu Z, Xu L, Sun X.

PLoS One. 2013 Nov 15;8(11):e79864. doi: 10.1371/journal.pone.0079864. eCollection 2013.

PMID:
24260311
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.

Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD, Hu ZB, Shen HB, Shu YQ.

Asian Pac J Cancer Prev. 2012;13(5):2157-62.

PMID:
22901187
[PubMed - indexed for MEDLINE]
Free Article
18.

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R.

Clin Cancer Res. 2008 Mar 15;14(6):1797-803. doi: 10.1158/1078-0432.CCR-07-1364.

PMID:
18347182
[PubMed - indexed for MEDLINE]
Free Article
19.

Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.

Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L.

Clin Lung Cancer. 2013 Jul;14(4):433-9. doi: 10.1016/j.cllc.2013.01.004. Epub 2013 Mar 22.

PMID:
23522953
[PubMed - indexed for MEDLINE]
20.

XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.

Feng J, Sun X, Sun N, Qin S, Li F, Cheng H, Chen B, Cao Y, Ma J, Cheng L, Lu Z, Ji J, Zhou Y.

Acta Biochim Biophys Sin (Shanghai). 2009 May;41(5):429-35.

PMID:
19430706
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk